Saltar al contenido
Merck

E5389

Sigma-Aldrich

Erythromycin

powder, suitable for cell culture, BioReagent

Sinónimos:

E-Mycin, Erythrocin

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C37H67NO13
Número de CAS:
Peso molecular:
733.93
Beilstein/REAXYS Number:
75279
EC Number:
MDL number:
UNSPSC Code:
12352207
PubChem Substance ID:
NACRES:
NA.76

product name

Erythromycin, BioReagent, suitable for cell culture

product line

BioReagent

form

powder

potency

≥850 μg per mg

technique(s)

cell culture | mammalian: suitable

impurities

≤0.1 EU/mg endotoxin

color

white

mp

133 °C

solubility

2 M HCl: 50 mg/mL (Stock solutions should be stored at 2-8 °C. Stable at 37 °C for 3 days.)
ethanol: soluble (Stock solutions should be stored at 2-8 °C. Stable at 37 °C for 3 days.)

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

mode of action

protein synthesis | interferes

SMILES string

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1

InChI key

ULGZDMOVFRHVEP-RWJQBGPGSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

Chemical structure: macrolide
Erythromycin is an antibiotic produced by growth of certain strains of Streptomyces erythreus. This product is composed largely of erythromycin A with small amounts of erythromycins B and C and is recommended for concentration at 100 mg/L. Concentrations between 50 and 200 mg/L have also proven effective in controlling bacterial growth. Erythromycin has been used as a motilin receptor agonist, to block respiratory glycoconjugate secretion in human airways in vitro, and for selecting plasmid-cured and recombinant lactococcus lactis MG1363 strains.

Application

Erythromycin has been used:
  • as a supplement for nutrient broth medium for culturing green fluorescent protein (GFP)- expressing E. coli
  • as a model drug to determine small intestinal (SMI) microtissue viability using the MTT assay{254
  • as an antibiotic to study the treatment strategies of chronic infections

Biochem/physiol Actions

Mode of Action: Erythromycin acts by inhibiting elongation at the transpeptidation step, specifically aminoacyl translocation from the A-site to P-site by binding to the 50s subunit of the bacterial 70s rRNA complex.

Antimicrobial Spectrum: This product acts against both gram-negative and gram-positive bacteria.

Caution

This product is stable in solution at 37°C for 3 days. Stock solutions should be stored at 2-8°C.

Preparation Note

This product is soluble in water at 2 mg/mL, with a 0.067% solution in water yielding a pH of 8.0-10.5. It is also soluble in ethanol at 50 mg/mL, yielding a clear, colorless to faint yellow solution. It is freely soluble in alcohol, acetone, chloroform, acetonitrile and ethyl acetate but forms salts with acids. All solutions should be protected from light.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Maopeng Wang et al.
International journal of biological macromolecules, 160, 736-740 (2020-06-03)
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic in the past four months and causes respiratory disease in humans of almost all ages. Although several drugs have been
Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections
Imamovic L, et al.
Cell, 172(1-2), 121-134 (2018)
Acoustofluidic bacteria separation
Li S, et al.
Journal of Micromechanics and Microengineering, 27(1), 015031-015031 (2016)
Geert Huys et al.
Antimicrobial agents and chemotherapy, 54(6), 2567-2574 (2010-04-14)
In a small-scale harmonization study involving nine laboratories in eight European countries, the intra- and interlaboratory performances of two commercially available systems, i.e., the VetMIC microplate system and Etest, for antimicrobial susceptibility testing of nonenterococcal lactic acid bacteria (NELAB) and
Won Jong Kim et al.
Cell host & microbe, 26(2), 228-239 (2019-08-06)
The mucosa is colonized with commensal Neisseria. Some of these niches are sites of infection for the STD pathogen Neisseria gonorrhoeae (Ngo). Given the antagonistic behavior of commensal bacteria toward their pathogenic relatives, we hypothesized that commensal Neisseria may negatively

Artículos

Antibiotics targeting bacterial ribosomes disrupt protein synthesis, a key process in bacterial growth inhibition.

Antibiotics targeting bacterial ribosomes disrupt protein synthesis, a key process in bacterial growth inhibition.

Antibiotics targeting bacterial ribosomes disrupt protein synthesis, a key process in bacterial growth inhibition.

Antibiotics targeting bacterial ribosomes disrupt protein synthesis, a key process in bacterial growth inhibition.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico